BillionToOne
The Research Associate Intern at BillionToOne contributes to the development of high-impact molecular diagnostic products for oncology and prenatal medicine, working alongside scientists to move assays from research prototypes to commercial products. The role involves designing, executing, and troubleshooting experiments, learning analytical methodologies, and presenting scientific findings in a fast-paced, collaborative environment. This on-site position in Menlo Park, CA, offers mentorship and hands-on experience with cutting-edge molecular techniques and next-generation sequencing.
Headquarters
Menlo Park, California, United States
Company Size
201-500 employees
Founded
2016
BillionToOne is a molecular diagnostics company that develops blood-based tests for prenatal screening and oncology, with a focus on detecting rare genetic variants in cell-free DNA. Its proprietary Quantitative Counting Template technology powers noninvasive prenatal screening and liquid biopsy assays used by healthcare providers and clinical laboratories. The company operates in the genomics and precision diagnostics industry.
BillionToOne Market Share Gains Raise Questions On Undervalued BLLN Stock
4 days ago
BillionToOne valued at $4.4 billion as shares surge in blockbuster Nasdaq debut
Nov 6, 2025
BillionToOne’s Single-Molecule Next-Generation Sequencing Platform Redefines Molecular Diagnostics for Prenatal and Oncology Care 404148
9 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BillionToOne.
BillionToOne Shares Surge Following Firm's $273M IPO
Nov 6, 2025